systolic heart failure
Conditions
Interventions
Bisoprolol group Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given. If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg. In t
Sponsors
Chiba-Nishi General Hospital Cardiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) primary disease: in principle, ischemic heart disease or dilated cardiomyopathy. 2) heart failure patients with 40% or less of left ventricular ejection fraction (LVEF). any NYHA class. 3) basic treatment: in principle, patients undergoing treatment with an ACE inhibitor(or ARB) OR a diuretic. 4) patients who had not undergone treatment with a beta-blocker (except eye drops) within 8 weeks before the registration date. 5) age: patient aged 20 to less than 85 on the day of obtaining written informed consent. 6) hospitalized/outpatient: either hospitalized or outpatient status. 7) gender: male of female 8) patients who had a detailed briefing of the trial with explanatory documents prior to the enrollment and voluntarily signed a consent form.
Exclusion criteria
Exclusion criteria: 1) patients who are considered not to be candidate for administration of beta blocker. 2) patients who are scheduled to undergo emergent dialysis or chronic dialysis patients. 3) patients who have developed acute coronary syndrome within 8 weeks before the registration day. 4) patients who need mechanical hemodynamical support (except for pace maker implantation OR ICD) 5) patients who have malignancy within 1 year prognosis. 6) patients who are pregnant, lactating, may become pregnant, or want to become pregnant during the study. 7) patients who are judged by an investor to be inappropriate for this study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The composite endpoint of major adverse cardiac events (MACEs) OR rehospitalization for heart failure | — |
Secondary
| Measure | Time frame |
|---|---|
| safety | — |
Countries
Japan
Contacts
Public ContactHiroyuki Yamamoto
Chiba-Nishi General Hospital Cardiology
Outcome results
None listed